Project Grant R01HL178822
Award Date 8/17/26
Completion Date 4/30/30
Dollars Obligated $764K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, NY 10016, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded New York University $1,692,126 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to dissect the molecular mechanisms and therapeutic potential of CHROMR, a long noncoding RNA upregulated in atherosclerotic cardiovascular disease. The research will map CHROMR-protein interfaces and design steric-blocking oligonucleotides to selectively disrupt the CHROMR-IRF2BP2 interaction, decoupling its pro-inflammatory...
- The National Heart, Lung, and Blood Institute awarded New York University a project grant of $179,496 on July 16, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate mechanisms of cardiovascular complications in respiratory viral infections. The research defines how viral infection, specifically SARS-CoV-2, drives macrophage metabolic and inflammatory reprogramming that accelerates atherosclerosis progression and establishes long-lasting vascular inflammation....
- The National Heart, Lung, and Blood Institute awarded Yale University $838,491 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to identify novel gene variants that drive endothelial cell activation during atherosclerotic cardiovascular disease. The recipient will elucidate mechanisms by which gain-of-function defects in ZFYVE21, an endosome-associated protein highly expressed in endothelial cells, contribute to endothelial cell activation and exacerbate...
- The National Heart, Lung, and Blood Institute awarded the University of California, Los Angeles $1.564 million on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the role of long noncoding RNAs and micropeptides in inflammation, lipid metabolism, and atherosclerosis. The project spans two research aims. Aim 1 examines a macrophage micropeptide named BRIK, testing its role in integrating metabolic and immune signaling and its contribution to...
- The National Heart, Lung, and Blood Institute awarded New York University's Long Island School of Medicine $2.728 million on September 24, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct research on reducing plasma cholesterol and atherosclerosis using C2, a synthetic microRNA-30c analog. The research will elucidate molecular mechanisms by which C2 administration reduces plasma cholesterol levels in mice with diet-induced hypercholesterolemia and LDL receptor...
- The National Institutes of Health National Heart, Lung and Blood Institute awarded Boston Children's Hospital $1,628,604 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct molecular research on atherosclerosis regulation, with performance through June 30, 2028. The project investigates endothelial dysfunction and chronic inflammation as critical regulators of plaque destabilization in atherosclerosis, focusing on the role of CD47 as a cell-surface...
- The National Heart, Lung, and Blood Institute awarded The Trustees of Columbia University in the City of New York $1,151,500 on March 9, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate macrophage biology in atherosclerosis and atherosclerosis-related cardiometabolic disease. The award funds a comprehensive program exploring the role of macrophage efferocytosis and resolution cycles in promoting fibrous cap thickening in atherosclerotic plaques and...
- The National Heart Lung and Blood Institute awarded Icahn School of Medicine at Mount Sinai $763,862 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the metabolic control of immune cell function in atherogenesis. The research examines the role of methylmalonic acid (MMA)—a byproduct of propionyl-CoA catabolism—in macrophage inflammatory processes that drive atherosclerotic cardiovascular disease. Preliminary data show that genetic deficiency of...
- The National Heart, Lung, and Blood Institute awarded New York University $737,762 on May 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate endothelial inflammation and its role in ischemia with nonobstructive coronary arteries (INOCA). The research examines coronary microvascular dysfunction as a key mechanism in INOCA, a chronic disorder characterized by angina, dyspnea, physical limitation, and impaired quality of life. The project directly harvests...
- The National Institutes of Health National Heart Lung and Blood Institute awarded New York University School of Medicine $1,690,440 on June 5, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate immune mechanisms that hinder atherosclerotic plaque regression in type 2 diabetes patients. The research focuses on gamma-delta (γδ) T cells, which preliminary work identified as expanded and cytotoxic within atherosclerotic plaques and circulating blood of type 2...